These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 14122799)

  • 21. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
    Gales AC; Reis AO; Jones RN
    J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymyxin B versus colistin: an update.
    Cai Y; Lee W; Kwa AL
    Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Resistance in vitro of Psudomonas aeruginosa to gentamicin compared with colistin and polymyxin B].
    Bergan T
    Nord Med; 1969 Jan; 81(3):73-5. PubMed ID: 4304204
    [No Abstract]   [Full Text] [Related]  

  • 24. PENTA-N-SULPHOMETHYL-POLYMYXIN B (THIOSPORIN) IN THE TREATMENT OF CORNEAL INFECTION.
    AINSLIE D
    Br J Ophthalmol; 1965 Feb; 49(2):98-101. PubMed ID: 14261720
    [No Abstract]   [Full Text] [Related]  

  • 25. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A; Kasiakou SK; Tam VH; Falagas ME
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinations of antimicrobial agents. I. The in vitro sensitivity of 100 strains of Pseudomonas aeruginosa to polymyxin B, colistin, carbenicillin, gentamicin and doxycycline and to various combinations of these antibiotics.
    Kuipers JS
    Arch Chir Neerl; 1975; 27(4):257-70. PubMed ID: 174496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SURFACE INFECTION WITH PSEUDOMONAS AERUGINOSA.
    WALKER HL; MASON AD; RAULSTON GL
    Ann Surg; 1964 Aug; 160(2):297-305. PubMed ID: 14209734
    [No Abstract]   [Full Text] [Related]  

  • 28. BACTERIOLOGIC STUDIES OF SOCKET SECRETIONS.
    SUIE T; HAVENER WH
    Am J Ophthalmol; 1964 May; 57():749-51. PubMed ID: 14167184
    [No Abstract]   [Full Text] [Related]  

  • 29. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves.
    Ziv G; Nouws JF; van Ginneken CA
    J Vet Pharmacol Ther; 1982 Mar; 5(1):45-58. PubMed ID: 6284955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].
    Akin FE; Bayram A; Balci I
    Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa.
    Luque S; Sorli L; Li J; Collado S; Barbosa F; Berenguer N; Horcajada JP; Grau S
    J Chemother; 2014 Apr; 26(2):122-4. PubMed ID: 24090909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility testing of the polymyxins: where are we now?
    Humphries RM
    Pharmacotherapy; 2015 Jan; 35(1):22-7. PubMed ID: 25329490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis.
    Tajima K; Miyake T; Koike N; Hattori T; Kumakura S; Yamaguchi T; Matsumoto T; Fujita K; Kuroda M; Ito N; Goto H
    J Infect Chemother; 2014 Jun; 20(6):343-9. PubMed ID: 24726376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?
    Giacobbe DR; Karaiskos I; Bassetti M
    Expert Opin Pharmacother; 2022 Jan; 23(1):5-8. PubMed ID: 34399631
    [No Abstract]   [Full Text] [Related]  

  • 36. Polymyxin B and polymyxin E; clinical and laboratory studies.
    KAGAN BM; KREVSKY D; MILZER A; LOCKE M
    J Lab Clin Med; 1951 Mar; 37(3):402-14. PubMed ID: 14824664
    [No Abstract]   [Full Text] [Related]  

  • 37. Resistance of spheroplasts and whole cells of Pseudomonas cepacia to polymyxin B.
    Manniello JM; Heymann H; Adair FW
    Antimicrob Agents Chemother; 1978 Sep; 14(3):500-4. PubMed ID: 213017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The susceptibility of enteropathogenic and non-enteropathogenic porcine Escherichia coli strains to polymyxins and other antibiotics.
    Larsen JL; Søgaard H
    Nord Vet Med; 1981; 33(9-11):393-402. PubMed ID: 6276857
    [No Abstract]   [Full Text] [Related]  

  • 39. THE CHEMICAL STRUCTURE OF POLYMYXIN E: THE IDENTITIES OF POLYMYXIN E1 WITH COLISTIN A AND OF POLYMYXIN E2 WITH COLISTIN B.
    SUZUKI T; HAYASHI K; FUJIKAWA K; TSUKAMOTO K
    J Biochem; 1965 Feb; 57():226-7. PubMed ID: 14299599
    [No Abstract]   [Full Text] [Related]  

  • 40. [TREATMENT OF DYSENTERY IN CHILDREN WITH POLYMYXIN AND BACTERIOPHAGE].
    SHEVIAKOVA OI; SHERMAN RZ; TATARINOVA SD
    Antibiotiki; 1964 Mar; 9():269-72. PubMed ID: 14198690
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.